<qa>  How many doses will each subject receive?This is a Phase I, first-in-human study of a vaccine against S. mansoni infection.The study will recruit 72 healthy adult males and non-pregnant females from a single clinical center to test two formulations of Sm-TSP-2 vaccine using the Alhydrogel only, and using Alhydrogel plus GLA-AF, each at 3 different doses: 10ug, 30ug, and 100ug. The study will use a dose-escalation cohort design, in which escalation to the next dose cohort will be determined based on evaluation of pre-defined escalation criteria requiring 7 day safety data to be examined after all subjects in the current cohort have received their first dose of vaccine. For each Cohort 1-3, an initial 5 subjects 2 Sm-TSP-2Alhydrogel, 2 Sm-TSP-2AlhydrogelGLA-AF, and 1 placebo will be enrolled, randomized, vaccinated, and have completed Visit 2 Day 3, before enrolling the rest of the cohort. As with dose-escalation decisions, evidence of significant reactogenicity will require further review prior to proceeding.Recruitment and enrollment into the study will occur on an ongoing basis, with each cohort being recruited and vaccinated in sequence. All subjects will be assigned investigational vaccine or placebo by randomization, and a double-blind design will be used i.e., neither the subject nor the investigator will be aware of the study product assigned: Sm-TSP-2Alhydrogel, Sm-TSP-2AlhydrogelGLA-AF, or placebo. Each subject will receive 3 vaccinations at Days 1, 57, and 113, and will be followed for a total of 12 months after the third dose. The study duration will be approximately 24 months, and subject participation duration will be approximately 16 months. The primary objective is to assess the safety and reactogenicity of ascending doses of Sm-TSP-2Alhydrogel 10ug, 30ug, or 100ug with or without GLA-AF vaccine given as three doses administered on Days 1, 57, and 113. The secondary objectives include: 1 to assess the IgG antibody response using an indirect enzyme-linked immunosorbent assay ELISA at Day 127; 2 to assess the IgG antibody response using an indirect enzyme-linked immunosorbent assay ELISA at 14 days after dose one and two and Day 203 and 293 3 and 6 months after the third dose of Sm-TSP-2Alhydrogel 10ug, 30ug, or 100ug with or without GLA-AF; 3 To assess the duration of the IgG antibody response using an indirect enzyme-linked immunosorbent assay ELISA following receipt of three doses of Sm-TSP-2Alhydrogel 10ug, 30ug, or 100ug with or without GLA-AF. 